Rheumatology Advance Access originally published online on February 4, 2009
Rheumatology 2009 48(6):613-617; doi:10.1093/rheumatology/ken513
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate
1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Correspondence to: Yvonne C. Lee, Division of Rheumatology, Immunology and Allergy, 75 Francis Street, PBB-B3, Boston, MA 02115, USA. E-mail: ylee9{at}partners.org
 |
Abstract |
|---|
Objectives. We examined the association between candidate single nucleotide polymorphisms (SNPs) and disease activity in RA patients on MTX.
Methods. Our population was drawn from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS), a prospective, observational cohort of RA patients. A total of 556 participants were genotyped using the Affymetrix 100K platform. Two hundred and sixty-two participants were on MTX therapy, including 120 on MTX monotherapy. The primary outcome was the disease activity score in 28 joints (DAS28-CRP). High disease activity was defined as DAS28-CRP >3.2. Low disease activity was defined as DAS28-CRP 
3.2. We studied three candidate alleles in the ATIC, ITPA and MTHFR genes for association with DAS28-CRP.
Results. Among participants on MTX monotherapy, those carrying the minor allele of ATIC SNP rs4673993 were more likely to have low disease activity (P = 0.01). None of the other SNPs was associated with disease activity. Among patients on any MTX (combination or monotherapy), the minor allele of ATIC rs4673993 was also associated with low disease activity (P = 0.04).
Conclusions. In this cross-sectional analysis, ATIC SNP rs4673993 was associated with low disease activity in patients on MTX. Further studies are needed to clarify the relationship between ATIC polymorphisms, disease activity and treatment response.
KEY WORDS: MTX, Adenosine, RA, Disease activity
Submitted 2 September 2008;
revised version accepted 19 December 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Beretta Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability Rheumatology, December 1, 2009; 48(12): 1619 - 1620. [Full Text] [PDF]
|
|
|
|
|
|
W. M. Kooloos, H.-J. Guchelaar, T. W. J. Huizinga, and J. A. M. Wessels Comment on: Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate Rheumatology, September 1, 2009; 48(9): 1176 - 1177. [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Lee, J. Cui, K. H. Costenbader, N. A. Shadick, M. E. Weinblatt, and E. W. Karlson Comment on: Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate: reply Rheumatology, September 1, 2009; 48(9): 1177 - 1177. [Full Text] [PDF]
|
|
|
|
|
|
T. Dervieux Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability Rheumatology, June 1, 2009; 48(6): 597 - 598. [Full Text] [PDF]
|
|